Histone deacetylase‐based dual targeted inhibition in multiple myeloma
Medicinal Research Reviews · 2023
DOI: 10.1002/med.21972 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2023. Verfasst von Angelica Ferro und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Multiple Myeloma, Histone Deacetylase Inhibitors, Histone Deacetylases, Molecular Targeted Therapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Committee of the University of Patras.
Abstract (Originalsprache)
Despite enormous advances in terms of therapeutic strategies, multiple myeloma (MM) still remains an incurable disease with MM patients often becoming resistant to standard treatments. To date, multiple combined and targeted therapies have proven to be more beneficial compared to monotherapy approaches, leading to a decrease in drug resistance and an improvement in median overall survival in patients. Moreover, recent breakthroughs highlighted the relevant role of histone deacetylases (HDACs) in cancer treatment, including MM. Thus, the simultaneous use of HDAC inhibitors with other conventional regimens, such as proteasome inhibitors, is of interest in the field. In this review, we provide a general overview of HDAC‐based combination treatments in MM, through a critical presentation of publications from the past few decades related to in vitro and in vivo studies, as well as clinical trials. Furthermore, we discuss the recent introduction of dual‐inhibitor entities that could have the same beneficial effects as drug combinations with the advantage of having two or more pharmacophores in one molecular structure. These findings could represent a starting‐point for both reducing therapeutic doses and lowering the risk of developing drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
- Synthetic Organic Chemistry Laboratory, Department of Chemistry, University of Patras, Patras, Greece.
- Laboratory of Biochemistry/Metastatic Signaling, Section of Genetics, Cell Biology, and Development, Department of Biology, University of Patras, Patras, Greece.
ORCID-Profile: Constantinos M Athanassopoulos, Muriel Cuendet
Förderung
- Research Committee of the University of Patras
Zitieren
APA
Ferro, A., Pantazaka, E., Athanassopoulos, C. M., & Cuendet, M. (2023). Histone deacetylase‐based dual targeted inhibition in multiple myeloma. Medicinal Research Reviews. https://doi.org/10.1002/med.21972
Vancouver
Ferro A, Pantazaka E, Athanassopoulos CM, Cuendet M. Histone deacetylase‐based dual targeted inhibition in multiple myeloma. Medicinal Research Reviews. 2023. doi:10.1002/med.21972
BibTeX
@article{Ferro2023,
author = {Ferro, Angelica and Pantazaka, Evangelia and Athanassopoulos, Constantinos M and Cuendet, Muriel},
title = {Histone deacetylase‐based dual targeted inhibition in multiple myeloma},
journal = {Medicinal Research Reviews},
year = {2023},
doi = {10.1002/med.21972}
}
EUVIMED